NewLink's indoximod shows positive action in early-stage study in aggressive type of brain tumor; shares up 3%

|About: NewLink Genetics Corpo... (NLNK)|By:, SA News Editor

NewLink Genetics (NLNK +3.4%) is up on below-average volume on its announcement of updated data from a Phase 1 clinical trial assessing indoximod + front-line radiation + maintenance chemo in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), a treatment-resistant and aggressive type of tumor that starts in the brain stem. The results were presented at the International Symposium of Pediatric Neuro-Oncology Annual Meeting in Denver, CO.

All 10 treated patients showed initial symptomatic improvement. Nine of the 10 remain on study, the longest being 8.5 months. Historically, median survival is only nine months.

On the safety front, an unspecified subset of patients experienced adverse events, including inflammation, which were actively managed.

Subscribe for full text news in your inbox